Micropulse Transscleral Cyclophotocoagulation: One-year Results and Comparison of two Different Laser Settings in Severe Glaucoma

Abstract Purpose: To evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-CPC) as a therapeutic option for severe glaucoma and to compare two different durations of treatment.Methods: Retrospective observational study of 40 eyes of 40 patients affected by different types of glaucoma treated with micropulse transscleral cyclophotocoagulation at 2000 mW for a duration of either 90 seconds per hemisphere (20 patients) or 80 seconds per hemisphere (20 patients) at 31.3% duty cycle. As main outcomes were evaluated postoperative intraocular pressure (IOP) and topical drugs reduction. Complications of the treatment and a comparative analysis of 2 different durations as secondary outcomes.Results: MP-CPC was successful in 26 patients (65%) and achieved a significant IOP reduction of 34.4% (p35 mmHg) and 1 case of cystoid macular oedema were the only complications detected. The comparison between the 90 seconds per hemisphere and the 80 seconds per hemisphere group did not show any statistically significant difference in IOP reduction, topical medication burden and incidence of complications.Conclusion: MP-CPC demonstrated to be an effective and safe treatment in lowering the IOP. Glaucoma topical medications did not significantly reduce. From our comparative analysis reducing the duration of treatment seems not to affect the outcomes.